Newly Diagnosed Acute Myeloid Leukemia (AML) Study

Newly Diagnosed Acute Myeloid Leukemia (AML) Study

Share this:

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.

PROTOCOL ID

COG # AAML1031

PROTOCOL DESCRIPTION

This study is for newly diagnosed patients with Acute Myeloid Leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the bones of the body where blood cells are made.

ELIGIBILITY CRITERIA

  • Patients must be less than 30 years of age at the time of study enrollment.
  • Be newly diagnosed with AML
  • Agree to have bone marrow specimens sent to special COG labs prior to the start of treatment and at various times during treatment.
  • Patients with Down's syndrome are not eligible

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376
wpmccarty@carilionclinic.org